The development of a CRISPR/Cas13a-based platform improves detection limits of SARS-CoV-2 RNA, highlighting a shift towards rapid RNA diagnostics.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mélanie Ott (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: